Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $17.00 Price Target at The Goldman Sachs Group

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price lowered by equities researchers at The Goldman Sachs Group from $19.00 to $17.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group‘s target price would suggest a potential downside of 2.96% from the stock’s current price.

Several other equities analysts also recently issued reports on RARE. JPMorgan Chase & Co. downgraded shares of Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $80.00 to $36.00 in a research note on Thursday, September 3rd. UBS Group started coverage on shares of Ultragenyx Pharmaceutical in a research note on Thursday, October 15th. They issued a “neutral” rating and a $16.00 price target for the company. Morgan Stanley increased their price objective on shares of Ultragenyx Pharmaceutical from $18.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Friday, September 18th. William Blair raised shares of Ultragenyx Pharmaceutical to a “hold” rating in a research report on Wednesday, September 23rd. Finally, HC Wainwright reduced their target price on Ultragenyx Pharmaceutical from $50.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday, September 3rd. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Ultragenyx Pharmaceutical has an average rating of “Hold” and an average target price of $33.55.

Ultragenyx Pharmaceutical Price Performance

NASDAQ:RARE traded up $0.89 during trading hours on Wednesday, hitting $17.52. The company’s stock had a trading volume of 2,857,596 shares, compared to its average volume of 2,851,260. The stock has a fifty day simple moving average of $16.64 and a 200-day simple moving average of $22.81. The company has a market capitalization of $1.73 billion, a P/E ratio of -3.00 and a beta of 0.37. Ultragenyx Pharmaceutical has a twelve month low of $12.73 and a twelve month high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.06). The firm had revenue of $173.00 million for the quarter, compared to analysts’ expectations of $182.49 million. During the same period in the prior year, the business earned ($1.81) earnings per share. The company’s revenue was up 8.2% on a year-over-year basis. On average, equities analysts predict that Ultragenyx Pharmaceutical will post -4.30 EPS for the current fiscal year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,066 shares of the company’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $15.27, for a total transaction of $107,897.82. Following the transaction, the chief financial officer owned 89,229 shares in the company, valued at approximately $1,362,526.83. This represents a 7.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 8,510 shares of company stock worth $127,561 in the last 90 days. Corporate insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. bought a new position in Ultragenyx Pharmaceutical in the 2nd quarter valued at about $355,746,000. Bank of America Corp DE acquired a new position in Ultragenyx Pharmaceutical during the 2nd quarter valued at about $38,347,000. Candriam S.C.A. increased its holdings in Ultragenyx Pharmaceutical by 37.1% during the 1st quarter. Candriam S.C.A. now owns 1,096,182 shares of the biopharmaceutical company’s stock worth $22,965,000 after purchasing an additional 296,798 shares in the last quarter. Jefferies Financial Group Inc. bought a new stake in Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $31,040,000. Finally, Eagle Health Investments LP bought a new stake in Ultragenyx Pharmaceutical during the 1st quarter worth approximately $18,522,000. 97.67% of the stock is owned by institutional investors.

More Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: The company reaffirmed its 2026 revenue and 2027 profitability outlook, and said cost reductions are expected to cut 2027 R&D expenses by at least 50% compared with 2025. Company results and outlook
• Positive Sentiment: Ultragenyx said the FDA approved GENGLYCOS and FAYUVI during the quarter. It also entered agreements to sell two priority review vouchers for a combined $413 million, adding a significant potential source of proceeds. Company results and outlook
• Positive Sentiment: Revenue increased 8.2% year over year to $173 million, while the quarterly loss narrowed to $1.16 per share from $1.81 a year earlier. Third-quarter results
• Neutral Sentiment: Analyst target revisions were mixed: Wells Fargo raised its target from $18 to $19 and kept an equal-weight rating, while Wedbush lowered its target from $25 to $22 and maintained a neutral rating.
• Negative Sentiment: Despite year-over-year improvement, Q3 results missed expectations: the $1.16-per-share loss was wider than analysts’ roughly $1.10 estimate, and $173 million in revenue was below the $182.49 million consensus. Q3 earnings report

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.